In one aspect there is provided a liquid herbal composition for relieving some or all of the symptoms of Seasonal Affective Disorder (SAD) and/or Chronic Fatigue Syndrome (CFS) or Myalgic Encephalomyelitis (ME). The liquid herbal composition preferably comprises therapeutically effective amounts of hydroalcoholic extracts of Bilberry, Eyebright, Goldenseal root, Ginkgo leaf, Passion flower and Raspberry leaf. The liquid herbal composition is preferably orally administered on a daily basis.

In one aspect there is provided a liquid herbal composition for relieving some or all of the symptoms of Seasonal Affective Disorder (SAD) and/or Chronic Fatigue Syndrome (CFS) or Myalgic Encephalomyelitis (ME). The liquid herbal composition preferably comprises therapeutically effective amounts of hydroalcoholic extracts of Bilberry, Eyebright, Goldenseal root, Ginkgo leaf, Passion flower and Raspberry leaf. The liquid herbal composition is preferably orally administered on a daily basis.

In one aspect there is provided a liquid herbal composition for relieving some or all of the symptoms of Seasonal Affective Disorder (SAD) and/or Chronic Fatigue Syndrome (CFS) or Myalgic Encephalomyelitis (ME). The liquid herbal composition preferably comprises therapeutically effective amounts of hydroalcoholic extracts of Bilberry, Eyebright, Goldenseal root, Ginkgo leaf, Passion flower and Raspberry leaf. The liquid herbal composition is preferably orally administered on a daily basis.

A pouched product adapted for release of a releasable component therefrom is provided herein. The pouched product can include a water-permeable fabric pouch formed so as to define a cavity therein, and a composition contained within the cavity of the water-permeable fabric pouch, the composition including one or more releasable components that are released from the composition under mouth conditions and that are capable of movement through the water-permeable fabric pouch. The composition includes nicotine and at least one particulate non-tobacco material. The pouched product also includes at least one capsule contained within the cavity of the water-permeable fabric pouch, the capsule having a capsule wall surrounding an inner payload comprising at least one botanical.

A pouched product adapted for release of a releasable component therefrom is provided herein. The pouched product can include a water-permeable fabric pouch formed so as to define a cavity therein, and a composition contained within the cavity of the water-permeable fabric pouch, the composition including one or more releasable components that are released from the composition under mouth conditions and that are capable of movement through the water-permeable fabric pouch. The composition includes nicotine and at least one particulate non-tobacco material. The pouched product also includes at least one capsule contained within the cavity of the water-permeable fabric pouch, the capsule having a capsule wall surrounding an inner payload comprising at least one botanical.

The problem to be solved by this invention is to provide a composition for inhibiting nerve cell injury caused by Aβ. This problem is solved by a composition for inhibiting nerve cell injury caused by Aβ, comprising a Kampo extract that contains a glycyrrhiza extract.

The problem to be solved by this invention is to provide a composition for inhibiting nerve cell injury caused by Aβ. This problem is solved by a composition for inhibiting nerve cell injury caused by Aβ, comprising a Kampo extract that contains a glycyrrhiza extract.

An improved dietary and/or therapeutic supplement composition comprising a quantity of a dietary and/or therapeutic supplement agent having a pH that upon ingestion with food or a beverage would limit the effectiveness of the agent and a sufficient amount of an alkaline electrolyte additive is provided in combination with the agent to raise the pH of the composition to a level of from about 8 to about 12.5 to increase the effectiveness and functional utilization of the agent while the composition is in the person's stomach.

An improved dietary and/or therapeutic supplement composition comprising a quantity of a dietary and/or therapeutic supplement agent having a pH that upon ingestion with food or a beverage would limit the effectiveness of the agent and a sufficient amount of an alkaline electrolyte additive is provided in combination with the agent to raise the pH of the composition to a level of from about 8 to about 12.5 to increase the effectiveness and functional utilization of the agent while the composition is in the person's stomach.

This document provides dietary supplement compositions. For example, multi-supplement compositions having combinations of dietary supplement formulations useful for human or animal consumption are provided.